Infusing CAR T-cells directly into the brain, rather than into the blood intravenously, could improve the immunotherapy’s effectiveness and produce fewer side effects, say researchers.
Plasticell, alongside Great Ormond Street Hospital and the UCL Institute of Child Health, have announced they will collaborate to develop technology to better develop and manufacture gene therapies.
Cel-Sci has won the breach of contract ruling against its former CRO inVentiv, after it “slowed down clinical development of Cel-Sci’s Phase III cancer immunotherapy,” says CEO.
WuXi Biologics has announced it will undertake its first collaborative project to develop and manufacture ‘heavy chain only’ antibodies, through an agreement with Harbour BioMed.
Novasep has launched a downstream processing tool that combines batch and continuous chromatography for monoclonal antibodies, recombinant proteins and blood factors.
WuXi Biologics has started building its antibody-drug conjugate (ADC) centre in Wuxi City, China, where it will offer biologics conjugate services for clients.
With $12m in Series C financing, AbSci is looking to tackle the antibody market by accelerating innovation and driving down manufacturing costs using its synthetic biology platform, says CEO.
Cellectis has built a switch into a chimeric antigen receptor (CAR) T-cell to provide an efficient way to eliminate the therapy if it becomes a threat to patient safety.
The Republic of Ireland’s competitive corporate tax rate represents a ‘stability’ that may not be found in other economies, says IDA Ireland executive.
The US FDA has approved Merck & Co.’s bestseller Keytruda for two additional oncology indications – cervical cancer, and relapsed primary mediastinal large B-cell lymphoma.
Eisai says it is creating a research facility for ‘genetics-guided dementia discovery’ in the US and joining a Japanese industry-academia-government collaboration aimed at developing nucleic acid-based drugs.
Many unanswered questions surrounding the nascent biosimilar market are creating challenges – though less regulated markets may benefit from 'less well defined' definitions, says analyst.
Parker Bioscience outlines its planned investment to meet demand as the industry shifts from traditional processes to biological – for which single-use products are critical, says exec.
WuXi Biologics has announced plans to build a $60m manufacturing facility – offering continuous manufacturing options – for clinical and commercial production in the US.
GE Healthcare has announced plans to install its second FlexFactory manufacturing platform for cell therapy, this time at Xiangxue Pharmaceutical’s site in Guangzhou, China.
Microbiome start-up will receive up to €454 million in upfront and milestone payments
UK-based Microbiotica will collaborate with Roche-owned biotechnology group Genentech in the hunt for new microbiome-based therapeutics and biomarkers for its inflammatory bowel disease (IBD) pipeline.
Cellectis’ third gene-edited, ‘off-the-shelf’ CAR T-cell candidate is set to enter clinical development after the US FDA approved an IND application for UCART22.
The US FDA has issued a complete response letter to Amgen for its biosimilar version of Roche’s Herceptin, marking the agency’s third trastuzumab candidate rejection this year.
Syngene International has inked a non-exclusive partnering agreement with the emerging immuno-oncology company Zumutor Biologics after collaborating for more than a year.
AveXis – a Novartis company – has added a manufacturing facility in North Carolina to its site network, where it will make investigational therapies for neurological genetic diseases.
Ultragenyx Pharmaceutical is transferring fill/finish activities for Mepsevvi from Rentschler Biopharma’s facility in Germany, to Rentschler Fill Solutions in Austria.